Medicenna Therapeutics Reports Q2 GAAP EPS of -$0.04, Exceeding Estimates
Medicenna Therapeutics (MDNA:CA) reported second-quarter financial results for the period ending September 30, 2026. The company's GAAP earnings per share (EPS) came in at -$0.04, which outperformed market expectations by $0.02. Despite the earnings beat, the company saw a decrease in its liquidity position. Cash and cash equivalents fell to $3.7 million as of September 30, 2026, down from $5.7 million reported at the end of June 2026. The company continues to focus on clinical developments, including updated results from its Phase I/II ABILITY-1 study.

Tickers: $MDNAF